Keywords: GlaxoSmithKline, Legal charge, Fourth-quarter, Avandia, Marketing practices

GlaxoSmithKline to take record $3.5 billion 4th-qtr charge due to Avandia

Article | 18 January 2011

Print This

In an announcement to the London Stock Exchange yesterday, pharma giant GlaxoSmithKline (LSE: GSK) revealed that it expects to take ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in